

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | | |
|--|--|---|---|
| 1. Name and Address of Reporting Person* <u>Kaldor Stephen W</u> (Last) (First) (Middle) <u>C/O CRINETICS PHARMACEUTICALS, INC.</u> <u>10222 BARNES CANYON ROAD, BLDG. #2</u> (Street) <u>SAN DIEGO CA 92121</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>07/17/2018</u> | 3. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [CRNX]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| | | | |
|---------------------------------|---|--|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|--|--|---|
| | Date Exercisable | Expiration Date | | | | |
| Stock Option (right to buy) | (1) | 12/10/2025 | Common Stock | 54,711 | 0.73 | D |
| Stock Option (right to buy) | (2) | 03/16/2028 | Common Stock | 15,197 | 1.91 | D |

Explanation of Responses:

- 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the stock option agreement between the Issuer and the Reporting Person.
- The option is exercisable as to vested and unvested shares. 1/24th of the shares subject to the option vested on April 16, 2018, and 1/24th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

/s/ Marc Wilson, attorney-in-fact 07/17/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.